Ulcerative Colitis Treatment Market

The Global Ulcerative Colitis Treatment Market is valued at USD 6958.9 Million in 2022 and is expected to reach USD 10394.7 Million by 2028 with a CAGR of 5.9% over the forecast period.

Global Ulcerative Colitis Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing number of case of ulcerative colitis and rising number of research and development activities in this field are some of the major factors anticipated to drive the growth of the Global Ulcerative Colitis Treatment Market within the forecast period.

Scope of Ulcerative Colitis Treatment Market–

Ulcerative colitis is an inflammatory bowel disease (IBD) which causes inflammation and ulcers (sores) in digestive tract. The inflammation can spread to entire colon. Diarrhea or urgent bowel movements, Abdominal (belly) cramping, tiredness, nausea, weight loss and anemia are some of symptoms of ulcerative colitis. The treatment options of ulcerative colitis are medication and surgery. The main purpose of the treatments is to reduce the inflammation. The severity of ulcerative colitis depends on the amount of inflammation and the location and treatment is given as per the severity of disease.

The Covid-19 pandemic has also impacted the global ulcerative colitis treatment market. The pandemic has led to delays in clinical trials, reduced access to healthcare for some patients, and changes in treatment protocols. These factors have had a negative impact on the market, with some patients experiencing delays in receiving treatment and some healthcare providers experiencing disruptions in the supply of medications. However, the long-term impact on the market remains to be seen, as there is still a high demand for effective treatments for ulcerative colitis.

The global ulcerative colitis treatment market is segmented on the basis of type, disease type distribution channel and region & country level. Based on type, the global ulcerative colitis treatment market is segmented into mild UC, moderate UC, and severe UC. On the basis of disease type, the market is segmented into ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis and fulminant colitis. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The regions covered in global ulcerative colitis treatment market report are North America, Europe, Asia-Pacific, Latin America, and Rest of the World. Based on country level, the market of global ulcerative colitis treatment market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, Southeast Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

Key Players of Ulcerative Colitis Treatment Market-

Some of the key players for global ulcerative colitis treatment market are -

• Pfizer
• Eli Lilly and Company
• GSK
• MSD
• Johnson & Johnson
• Novartis
• AstraZeneca
• Roche
• Sanofi
• MSD
• Bayer
• AbbVie
• Eli Lilly and Company
• Abbott Laboratories
• others

Ulcerative Colitis Treatment Market Segmentation-

By Type:

• Mild UC
• Moderate UC
• Severe UC

By Disease Type:

• Ulcerative Proctitis
• Proctosigmoiditis
• Left-sided Colitis
• Pancolitis or Universal Colitis
• Fulminant Colitis

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Increasing Number of Cases with Ulcerative Colitis and Rising Number of Research and Development Activities in This Field are Some of the Major Factors Anticipated to Drive the Market Growth

One of the major factors driving the growth of the global ulcerative colitis treatment market is increasing number of cases of ulcerative colitis. For instance; Research conducted by Crohn’s & Colitis UK in 2022 suggests one in every 123 people in the UK have either Crohn’s disease or ulcerative colitis. This amounts to a total of nearly half a million people in the UK living with IBD. Hence, this increasing number of cases of ulcerative colitis will increase the expansion of the ulcerative colitis treatment market.

In addition, rising number of research and development activities in this field and growing focus by key players on collaboration and partnerships to develop novel treatment options for the management of ulcerative colitis are also supplementing the market growth. For example; as per news published on February 14^th, 2018 for development of novel treatment for ulcerative colitis the Regentys a regenerative medicine company and Cook Biotech Inc. announced partnership.

Moreover, growing number of product approvals in the ulcerative colitis treatment market is further boosting growth to the market. For example; on May 27^th, 2020; the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for treatment of moderate to severe active ulcerative colitis in adults announced by the company Bristol Myers Squibb officials.

However, high cost of ulcerative colitis treatment in developing countries may hamper the market growth. In spite of that, growing availability ulcerative colitis treatment drugs in online pharmacies may provide more growth opportunities for the further growth of the market.

The North America is Expected to Dominate Global Ulcerative Colitis Treatment Market

The North America is expected to dominate the global ulcerative colitis market, owing to the presence of key players, the increasing prevalence of ulcerative colitis, and rising number of research activities and growing number of product approvals for the treatment of ulcerative colitis in this region. For instance; ulcerative colitis affect 40 to 240 in 100,000 people in Nort America estimated by National Library of Medicine. In addition, presence of key players focusing on continuous research are also contributing to the growth of the market in this region. For instance; in Canada, Eli Lilly and Company announced mirikizumab resulted the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficiency and protection of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC) in March 2021. Moreover, growing number of product approvals for the treatment of ulcerative colitis from the United States Food and Drug Administration, Health Canada, and others are also boosting the growth of the market. For instance; the use of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis was approved by the U.S. Food and Drug Administration on 30^th May 2018.

Europe is expected to witness a significant growth in the global ulcerative colitis treatment due to growing investments, highly developed healthcare infrastructure and rising number of research and development activities in this field in this region. For instance; as per news published on May 22^nd, 2022, completion of US$64 million funding to additional the development of STI-0529 for the treatment of moderate to severe ulcerative was announced by Sublimity Therapeutics Limited.

News-

RINVOQ Received FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

On March 17^th, 2022; The U.S. Food and Drug Administration (FDA) approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) announced by AbbVie. The approval of FDA is supported by data from the SELECT program, one of the largest registrational Phase 3 programs in RA with approximately 4,400 patients evaluated across all treatment arms in five studies.

FDA Approved New Treatment for Ulcerative Colitis

On May 30^th, 2018; The U.S. Food and Drug Administration approved the use Xeljanz (tofacitinib) for adults with moderately to severely active ulcerative colitis. This was the first oral medication approved for chronic use in this indication. The three controlled clinical trials were studies for effectiveness of Xeljanz for the treatment of moderately to severely active ulcerative colitis.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 6958.9 Million
Base year considered	2021
Forecast Period CAGR %:	5.9%
Market Size Expected in 2028:	USD 10394.7 Million
Tables, Charts & Figures:	175
Pages	300
Key Players/Companies	Pfizer, Eli Lilly and Company, GSK, MSD, Johnson & Johnson, Novartis, AstraZeneca, Roche, Sanofi, MSD, Bayer, AbbVie, Eli Lilly and Company, Abbott Laboratories, and others
Segments Covered	By Type, By Disease Type, By Distribution Channel
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa